SCLN was up 12% and is still up 11.14% at present with volume of > 346Ks about 1/2 its ADV
The stock is up for 3rd day on a roll as it faces the resistance at the $4 level.<g>
bigcharts.marketwatch.com
It announced last week that it will present at two upcoming investor conferences:
Rodman & Renshaw Annual London Investment China Conference next Monday in London.
And the Oppenheimer Annual China Dragon Call Conference on Tuesday in N.Y.
SCLN main product is ZADAXIN for the treatment of hepatitis B and hepatitis C viruses, and certain cancers, as well as for use as a vaccine adjuvant or as a chemotherapy adjuvant for cancer patients with weakened immune systems.
The drug has been approved in approximately 30 countries, primarily in Asia, eastern Europe, the Middle East, and Latin America, and has completed a PII for treatment of stage IV melanoma..
SCLN is also developing SCV-07, which is in a PII for treatment of oral mucositis and hepatitis C virus.
It also has commercialization rights for DC Bead, a product candidate for the treatment of advanced liver cancer in China, as well as for ondansetron RapidFilm, an oral thin film formulation of ondansetron to treat and prevent nausea and vomiting caused by chemotherapy, radiotherapy, and surgery in China and Vietnam.
SCLN is headquartered in Foster City, CA.
SCLN has 4Qs of better revenues and earnings have improved at triple digits.<g>
The EE for the current Yr, are around $0.36 and $0.45 for 2011
SCLN has no significant LTD and has +CF
The short ratio increased 7% in the last month and is > 3x its ADV.<g>
The ACTAY is $7.08 but I will keep a target at $6 <g>
bigcharts.marketwatch.com
Bernard |
